tiprankstipranks
Advertisement

GSIE - ETF AI Analysis

Compare

Top Page

GSIE

Goldman Sachs ActiveBeta International Equity ETF (GSIE)

Rating:66Neutral
Price Target:
GSIE, the Goldman Sachs ActiveBeta International Equity ETF, has a solid overall rating driven mainly by high-quality global leaders like ASML, HSBC, Novartis, and AstraZeneca, which show strong financial performance, positive earnings sentiment, and generally supportive technical trends. Some holdings such as Roche and Banco Santander introduce caution due to valuation concerns, leverage, and regional or litigation risks, and the fund’s focus on large international financial and healthcare names means investors should be aware of sector and regional risk concentration.
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year and over the past few months, showing positive momentum.
Well-Performing Top Holdings
Several of the largest positions, including major semiconductor, banking, and pharmaceutical companies, have shown strong or steady performance, supporting the fund’s returns.
Broad International Diversification
The fund spreads its investments across many countries and sectors, which helps reduce the impact of problems in any single market or industry.
Negative Factors
Moderate Expense Ratio
While not extremely high, the fund’s fees are higher than the cheapest index ETFs, which slightly reduces net returns over time.
Financial Sector Sensitivity
A sizable allocation to financial companies means the fund could be more affected if banks or financial markets face stress.
Mixed Performance Among Top Holdings
Although many top holdings are performing well, at least one major position has been weak, which can drag on overall results if that continues.

GSIE vs. SPDR S&P 500 ETF (SPY)

GSIE Summary

GSIE is the Goldman Sachs ActiveBeta International Equity ETF, which follows the Stuttgart Goldman Sachs ActiveBeta International Equity index and invests in stocks from many countries outside the U.S., like Japan, the UK, and Europe. It holds a wide mix of sectors, including financials, industrials, and healthcare, with well-known companies such as ASML Holding, Royal Bank of Canada, HSBC, Novartis, and AstraZeneca. Investors might consider GSIE to diversify beyond the U.S. and seek long-term growth from global markets. A key risk is that international stocks can go up and down with global market and currency swings.
How much will it cost me?The expense ratio for the Goldman Sachs ActiveBeta International Equity ETF (GSIE) is 0.25%, which means you’ll pay $2.50 per year for every $1,000 invested. This is lower than average for actively managed ETFs because it uses a factor-based strategy rather than traditional stock-picking, keeping costs relatively modest.
What would affect this ETF?The GSIE ETF, with its focus on developed markets outside the U.S., could benefit from economic growth in Europe and Asia, particularly if industries like financials and technology, which have significant weight in the fund, experience expansion. However, it may face challenges from rising interest rates or geopolitical tensions that could negatively impact international markets and sectors like financials and consumer cyclical. Additionally, regulatory changes in key regions or currency fluctuations could influence the ETF's performance.

GSIE Top 10 Holdings

GSIE leans heavily on global financials and healthcare, with banks like HSBC, Royal Bank of Canada, and Toronto-Dominion quietly powering the fund thanks to steady, rising share prices. European pharma giants Novartis and Roche add a defensive backbone, helping smooth out bumps in the market. On the growth side, chip-equipment leader ASML and Japan’s Advantest have been strong longer-term drivers, though their recent momentum looks a bit mixed. AstraZeneca, meanwhile, is losing steam, slightly dragging on returns. Overall, it’s a diversified developed-markets ex-U.S. mix, not dominated by any single name.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV2.11%$126.20M€547.84B141.04%
76
Outperform
HSBC Holdings1.17%$69.65M£270.81B71.70%
80
Outperform
Royal Bank Of Canada1.13%$67.50M$290.86B62.90%
75
Outperform
Novartis AG1.03%$61.52MCHF231.75B34.41%
80
Outperform
Roche Holding AG1.02%$60.85M$348.96B38.80%
73
Outperform
Advantest0.93%$55.44M¥22.67T190.00%
75
Outperform
Banco Santander0.88%$52.76M€180.75B66.93%
73
Outperform
Toronto Dominion Bank0.80%$47.83M$202.51B65.29%
74
Outperform
AstraZeneca0.78%$46.84M$264.13B13.76%
80
Outperform
Banco Bilbao Vizcaya Argentaria0.64%$38.33M€134.72B64.69%
76
Outperform

GSIE Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
45.67
Positive
100DMA
44.76
Positive
200DMA
43.61
Positive
Market Momentum
MACD
0.36
Negative
RSI
62.71
Neutral
STOCH
91.71
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSIE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 46.20, equal to the 50-day MA of 45.67, and equal to the 200-day MA of 43.61, indicating a bullish trend. The MACD of 0.36 indicates Negative momentum. The RSI at 62.71 is Neutral, neither overbought nor oversold. The STOCH value of 91.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSIE.

GSIE Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$5.99B0.25%
66
Neutral
$5.49B0.40%
68
Neutral
$4.17B0.30%
69
Neutral
$4.08B0.25%
68
Neutral
$3.65B0.16%
65
Neutral
$2.90B0.43%
60
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GSIE
Goldman Sachs ActiveBeta International Equity ETF
47.25
8.89
23.18%
LVHI
Legg Mason International Low Volatility High Dividend ETF
IMTM
iShares MSCI Intl Momentum Factor ETF
IDMO
Invesco S&P International Developed Momentum ETF
INTF
iShares MSCI Intl Multifactor ETF
PXF
Invesco FTSE RAFI Developed Markets ex-U.S. ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement